Is eDIL3 a novel regulator of epithelial-mesenchymal transition controlling early recurrence of hepatocellular carcinoma?
EDIL3-mediated activation of TGF-β and ERK signaling could provide therapeutic implications for HCC.
The results showed that we could use PBMCs to pharmacodynamically predict the patients with a poor response to cyclosporine therapy. These patients may require larger doses of cyclosporine or alternative approaches to treatment. The patients with PBMCs sensitive to cyclosporine should be evaluated for treatment with smaller doses of the drug to avoid serious side effects.